Melacine vaccine data

A meta-analysis of survival data from 26 published studies for 1,731 patients with disseminated melanoma showed that those treated with Melacine vaccine had a median survival of 11 months compared to 7.8 months for the other evaluable therapies, including chemotherapy, IL-2, lymphokine-activated killer cells, and other melanoma vaccines.

Final data collection for an ongoing Phase III trial will occur mid-year. ...